Kalvista Pharmaceuticals (NASDAQ:KALV) Stock Rating Lowered by BidaskClub

BidaskClub cut shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a hold rating to a sell rating in a research report report published on Tuesday, BidAskClub reports.

KALV has been the topic of a number of other reports. ValuEngine downgraded shares of Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. Needham & Company LLC raised their target price on shares of Zuora from $27.00 to $30.00 and gave the company a strong-buy rating in a research note on Wednesday, March 20th. Zacks Investment Research downgraded shares of Horiba from a hold rating to a sell rating in a research note on Wednesday, May 22nd. Finally, Roth Capital reaffirmed a buy rating on shares of Kalvista Pharmaceuticals in a research note on Tuesday, May 28th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of Buy and a consensus target price of $29.40.

Shares of KALV opened at $17.31 on Tuesday. The company has a 50 day moving average of $20.59. The stock has a market capitalization of $298.60 million, a P/E ratio of -11.31 and a beta of 2.12. Kalvista Pharmaceuticals has a 1-year low of $7.95 and a 1-year high of $34.92.

In other Kalvista Pharmaceuticals news, insider Christopher Yea sold 7,355 shares of the stock in a transaction that occurred on Monday, April 22nd. The shares were sold at an average price of $26.04, for a total transaction of $191,524.20. Following the transaction, the insider now directly owns 90,324 shares in the company, valued at $2,352,036.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Thomas Andrew Crockett sold 10,000 shares of the stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $24.80, for a total transaction of $248,000.00. Following the transaction, the chief executive officer now owns 258,810 shares in the company, valued at $6,418,488. The disclosure for this sale can be found here. Insiders have sold 25,501 shares of company stock worth $645,553 over the last quarter. Company insiders own 38.40% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the business. Flinton Capital Management LLC bought a new position in shares of Kalvista Pharmaceuticals in the fourth quarter worth approximately $26,000. Bank of Montreal Can grew its holdings in shares of Kalvista Pharmaceuticals by 28.5% in the first quarter. Bank of Montreal Can now owns 5,824 shares of the specialty pharmaceutical company’s stock worth $166,000 after purchasing an additional 1,292 shares during the last quarter. Marshall Wace North America L.P. bought a new position in shares of Kalvista Pharmaceuticals in the first quarter worth approximately $175,000. Telemetry Investments L.L.C. grew its holdings in shares of Kalvista Pharmaceuticals by 55.5% in the fourth quarter. Telemetry Investments L.L.C. now owns 24,883 shares of the specialty pharmaceutical company’s stock worth $491,000 after purchasing an additional 8,883 shares during the last quarter. Finally, Tibra Equities Europe Ltd bought a new position in shares of Kalvista Pharmaceuticals in the first quarter worth approximately $727,000. Institutional investors and hedge funds own 80.64% of the company’s stock.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Further Reading: Understanding Analyst Recommendations

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.